Copyright
©The Author(s) 2015.
World J Pharmacol. Mar 9, 2015; 4(1): 96-116
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.96
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.96
Figure 2 Proposed mechanisms by which upregulation of hypoxia-inducible factor-2α induced by sorafenib contributes to the resistance by activating the transforming growth factor-α/epidermal growth factor receptors pathway in hepatocellular carcinoma cells.
ARNT: Aryl hydrocarbon receptor nuclear translocator; EGFR: Epidermal growth factor receptor; ERK: Extracellular signal-regulated kinase; HIF-1α: Hypoxia-inducible factor-1α; HIF-2α: Hypoxia-inducible factor-2α; PHD: Prolyl hydroxylase; STAT3: Signal transducer and activator of transcription 3; TGF-α: Transforming growth factor-α; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor. Reprinted from ref. [100] with permission from Elsevier.
- Citation: Cuestas ML, Oubiña JR, Mathet VL. Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World J Pharmacol 2015; 4(1): 96-116
- URL: https://www.wjgnet.com/2220-3192/full/v4/i1/96.htm
- DOI: https://dx.doi.org/10.5497/wjp.v4.i1.96